Exosome-based biomarkers for cardiac sarcoidosis activity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study will collect and bank peripheral blood samples from adults with suspected or confirmed cardiac sarcoidosis to analyze exosome-derived signatures. The goal is to identify unique biomarkers in exosomes that correlate with disease activity, using participants with active and inactive disease. The study will leverage standard FDG-PET imaging and build a prospective biobank for future analyses. No experimental treatment is given; analyses focus on molecular signatures in blood. Mayo Clinic in Rochester serves as the lead site for this work.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Adults ≥18 years.
* Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
* Undergoing FDG-PET as part of standard care.
* Ability to provide informed consent.

Exclusion Criteria

• Inability to provide informed consent.

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Andrew Rosenbaum, MD — Mayo Clinic
• Study coordinator: Anna Pick
• Email: pick.anna@mayo.edu
• Phone: 507-255-0630

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Al[18F]F-NOTA-folate PET imaging in suspected cardiac sarcoidosis and infective endocarditis

  This diagnostic test uses a folate-based PET tracer to see if it can help identify inflammation or infection in the heart for people with suspected cardiac sarcoidosis or infective endocarditis.

  Recruiting Turku University Hospital · Turku · NCT07814222

• Multimodal analysis of heart biopsy samples

  This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07359690

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

• Tc-99m Tilmanocept SPECT/CT imaging for detecting cardiac sarcoidosis

  This trial tries to see if a Tc-99m Tilmanocept SPECT/CT scan can detect cardiac sarcoidosis in adults.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT07159074

• Evaluating rilonacept for treating cardiac sarcoidosis

  This study tests if adding a new drug called rilonacept to regular treatment can help adults with cardiac sarcoidosis reduce inflammation in their hearts.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Baltimore, Maryland and 1 other locations · NCT06660732

• Using SGLT1/2 inhibitors to improve heart imaging in healthy volunteers

  This study is testing whether a new diabetes medication can help improve heart imaging in healthy volunteers by better controlling how the heart uses sugar during scans.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT06510894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.